Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis : A cost-effectiveness analysis

Circulation: Cardiovascular Quality and Outcomes

Volumn 6, Issue 3, 2013, Pages 343-351

  Irlam, James ^a   Mayosi, Bongani M ^b   Engel, Mark ^b   Gaziano, Thomas A ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cost benefit analysis; Prevention; Rheumatic heart disease

Indexed keywords

PENICILLIN DERIVATIVE;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PHARYNGITIS; PRESCHOOL CHILD; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SCHOOL CHILD; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; THROAT CULTURE;

COST-BENEFIT ANALYSIS; PREVENTION; RHEUMATIC HEART DISEASE;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DEVELOPING COUNTRIES; DRUG COSTS; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; PENICILLINS; PHARYNGITIS; PREVALENCE; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; SOUTH AFRICA; TREATMENT OUTCOME; URBAN HEALTH SERVICES;

EID: 84884474630     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.111.000032     Document Type: Article

References (50)

1. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet. 2005;366:155-168.
2. Michaud C, Rammohan R, Narula J. Cost-effectiveness analysis of intervention strategies for reduction of the burden of rheumatic heart disease. In: Narula J, Virmani R, Reddy KS, Tandon R, eds. Rheumatic Fever. Washington, WA: American Registry of Pathology; 1999:485-497.
3. Pastore S, De Cunto A, Benettoni A, Berton E, Taddio A, Lepore L. The resurgence of rheumatic fever in a developed country area: the role of echocardiography. Rheumatology (Oxford). 2011;50:396-400.
4. Omurzakova NA, Yamano Y, Saatova GM, Mirzakhanova MI, Shukurova SM, Kydyralieva RB, Jumagulova AS, Seisenbaev ASh, Nishioka K, Nakajima T. High incidence of rheumatic fever and rheumatic heart disease in the republics of Central Asia. Int J Rheum Dis. 2009;12: 79-83.
5. Karthikeyan G, Mayosi BM. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa? Circulation. 2009;120:709-713.
6. Milne RJ, Lennon D, Stewart J, Scuffham P, Hoorn SV, Cooke J, Remeny B, Finucane K, Wilson N, Nicholson R. Economic evaluation of a school intervention to reduce the risk of rheumatic fever. A report to the Ministry of Health, 2011.
7. Gaziano TA. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa. Heart. 2008;94:140-144.
8. Fischer Walker CL, Rimoin AW, Hamza HS, Steinhoff MC. Comparison of clinical prediction rules for management of pharyngitis in settings with limited resources. J Pediatr. 2006;149:64-71.
9. Rimoin AW, Hamza HS, Vince A, Kumar R, Walker CF, Chitale RA, da Cunha AL, Qazi S, Steinhoff MC. Evaluation of the WHO clinical decision rule for streptococcal pharyngitis. Arch Dis Child. 2005;90: 1066-1070.
10. Steinhoff MC, Walker CF, Rimoin AW, Hamza HS. A clinical decision rule for management of streptococcal pharyngitis in low-resource settings. Acta Paediatr. 2005;94:1038-1042.
11. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev. 2002;3:CD002227.
12. The National Department of Health, South Africa. National guidelines on primary prevention and prophylaxis of rheumatic heart fever and rheumatic heart disease for health professionals at primary level. South African Medical Journal. 1999;89(Suppl 2):C91-C94.
13. Stollerman GH. Penicillin for streptococcal pharyngitis: has anything changed? Hosp Pract (Off Ed). 1995;30:80-83.
14. Tsevat J, Kotagal UR. Management of sore throats in children: a costeffectiveness analysis. Arch Pediatr Adolesc Med. 1999;153:681-688.
15. Denny FW. T. Duckett Jones and rheumatic fever in 1986. T. Duckett Jones memorial lecture. Circulation. 1987;76:963-970.
16. Robertson KA, Volmink JA, Mayosi BM. Lack of adherence to the National Guidelines on the Prevention of Rheumatic Fever. S Afr Med J. 2005;95:52-56.
17. Neuner JM, Hamel MB, Phillips RS, Bona K, Aronson MD. Diagnosis and management of adults with pharyngitis: a cost-effectiveness analysis. Ann Intern Med. 2003;139:113-122.
18. Feinstein AR, Stern EK, Spagnuolo M. The prognosis of acute rheumatic fever. Am Heart J. 1964;68:817-834.
19. Hillner BE, Centor RM. What a difference a day makes: a decision analysis of adult streptococcal pharyngitis. J Gen Intern Med. 1987;2:244-250.
20. Van Howe RS, Kusnier LP II. Diagnosis and management of pharyngitis in a pediatric population based on cost-effectiveness and projected health outcomes. Pediatrics. 2006;117:609-619.
21. Lieu TA, Fleisher GR, Schwartz JS. Cost-effectiveness of rapid latex agglutination testing and throat culture for streptococcal pharyngitis. Pediatrics. 1990;85:246-256.
22. Dippel DW, Touw-Otten F, Habbema JD. Management of children with acute pharyngitis: a decision analysis. J Fam Pract. 1992;34:149-159.
23. Carapetis JR, Currie BJ, Mathews JD. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? Epidemiol Infect. 2000;124:239-244.
24. Michaud CM, Trejo-Gutierrez J, Cruz C, Pearson T. Rheumatic heart disease. In: Jamison DT, Mosely WH, Measham AR, Bobadilla JL, eds. Disease Control Priorities in Developing Countries. New York: Oxford University Press; 1993:221-232.
25. Kumar R, Raizada A, Aggarwal AK, Ganguly NK. A community-based rheumatic fever/rheumatic heart disease cohort: twelve-year experience. Indian Heart J. 2002;54:54-58.
26. Grayson S, Horsburgh M, Lennon D. An Auckland regional audit of the nurse-led rheumatic fever secondary prophylaxis programme. N Z Med J. 2006;119:U2255.
27. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord. 2005;5:11.
28. Padmavati S, Sharma KB, Jayaram O. Epidemiology and prophylaxis of rheumatic fever in Delhi-a five year follow-up. Singapore Med J. 1973;14:457-461.
29. Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2006:CD000023.
30. Webb KH. Does culture confirmation of high-sensitivity rapid streptococcal tests make sense? A medical decision analysis. Pediatrics. 1998;101:E2.
31. Statistics South Africa. Statistics South Africa annual report 2007/8. Statistics South Africa. 2008.
32. World Health Organization. The World Health Report 2006. Working together for health. 2006.
33. Kellogg JA. Suitability of throat culture procedures for detection of group A streptococci and as reference standards for evaluation of streptococcal antigen detection kits. J Clin Microbiol. 1990;28:165-169.
34. McIntyre D. Shield work package 5 report: modelling the estimated resource requirements of alternative health care financing reforms in South Africa. Health Economics Unit, University of Cape Town. 2010.
35. Health and Medical Publishing Group of the South African Medical Association. Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town. South African medicines formulary. 2010.
36. The National Department of Health, South Africa. Standard treatment guidelines and essential drugs list for South Africa; hospital level (adults). 2006.
37. Karthikeyan G, Zühlke L, Engel M, Rangarajan S, Yusuf S, Teo K, Mayosi BM. Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study. Am Heart J. 2012;163:535-540.e1.
38. The EuroQol Group. Euroqol: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
39. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-1108.
40. World Bank. World Development Indicators. Washington, DC: The World Bank; 2012.
41. Sliwa K, Carrington M, Mayosi BM, Zigiriadis E, Mvungi R, Stewart S. Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: insights from the heart of Soweto study. Eur Heart J. 2010;31:719-727.
42. Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart. 2008;94:1534-1540.
43. World Health Organization. Who-choice. Choosing interventions that are cost-effective. Geneva, Switzerland; 2003.
44. Catanzaro FJ, Stetson CA, Morris AJ, Chamovitz R, Rammelkamp CH Jr, Stolzer BL, Perry WD. The role of the streptococcus in the pathogenesis of rheumatic fever. Am J Med. 1954;17:749-756.
45. Siegel A, Johhson E, Stollerman G. Controlled studies of streptococcal pharyngitis in a pediatric population. NEJM. 1961;265:559-566.
46. Land MA, Bisno AL. Acute rheumatic fever: vanishing disease in suburbia. JAMA. 1983;249:895-898.
47. Schmidt WM. Health and welfare of Colonial American children. Am J Dis Child. 1976;130:694-701.
48. Arguedas A, Mohs E. Prevention of rheumatic fever in Costa Rica. J Pediatr. 1992;121:569-572.
49. Bach JF, Chalons S, Forier E, Elana G, Jouanelle J, Kayemba S, Delbois D, Mosser A, Saint-Aime C, Berchel C. 10-year educational programme aimed at rheumatic fever in two French Caribbean islands. Lancet. 1996;347:644-648.
50. Nordet P, Lopez R, Dueñas A, Sarmiento L. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience (1986-1996-2002). Cardiovasc J Afr. 2008;19:135-140.